Robert B. Jenkins

64.7k total citations · 17 hit papers
400 papers, 34.9k citations indexed

About

Robert B. Jenkins is a scholar working on Genetics, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Robert B. Jenkins has authored 400 papers receiving a total of 34.9k indexed citations (citations by other indexed papers that have themselves been cited), including 149 papers in Genetics, 135 papers in Pulmonary and Respiratory Medicine and 133 papers in Molecular Biology. Recurrent topics in Robert B. Jenkins's work include Glioma Diagnosis and Treatment (136 papers), Cancer Genomics and Diagnostics (52 papers) and Prostate Cancer Treatment and Research (52 papers). Robert B. Jenkins is often cited by papers focused on Glioma Diagnosis and Treatment (136 papers), Cancer Genomics and Diagnostics (52 papers) and Prostate Cancer Treatment and Research (52 papers). Robert B. Jenkins collaborates with scholars based in United States, Canada and United Kingdom. Robert B. Jenkins's co-authors include Jan C. Buckner, Bernd W. Scheithauer, Edith A. Perez, McKinsey L. Goodenberger, Gail H. Vance, Patrick L. Fitzgibbons, Giuseppe Viale, Michael F. Press, Michael Bilous and Lisa M. McShane and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.

In The Last Decade

Robert B. Jenkins

391 papers receiving 34.2k citations

Hit Papers

Recommendations for Human Epidermal Growt... 1999 2026 2008 2017 2013 2018 2013 1999 2013 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
    2013 3.1k citations Robert B. Jenkins, Edith A. Perez et al. Journal of Clinical Oncology profile →
  2. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
    2018 1.5k citations Robert B. Jenkins et al. Journal of Clinical Oncology profile →
  3. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
    2013 1.3k citations Robert B. Jenkins, Edith A. Perez et al. profile →
  4. Efficacy of Bilateral Prophylactic Mastectomy in Women with a Family History of Breast Cancer
    1999 982 citations Robert B. Jenkins et al. profile →
  5. Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology
    2013 967 citations Robert B. Jenkins et al. profile →
  6. Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402
    2012 757 citations Gregory Cairncross, Meihua Wang et al. Journal of Clinical Oncology profile →
  7. Genetics of adult glioma
    2012 671 citations Robert B. Jenkins et al. profile →
  8. Alterations of Chromosome Arms 1p and 19q as Predictors of Survival in Oligodendrogliomas, Astrocytomas, and Mixed Oligoastrocytomas
    2000 643 citations Thomas J. Borell, Bernd W. Scheithauer et al. Journal of Clinical Oncology profile →
  9. BubR1 insufficiency causes early onset of aging-associated phenotypes and infertility in mice
    2004 586 citations Rajiv Kumar, Robert B. Jenkins et al. profile →
  10. cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV”
    2018 553 citations Robert B. Jenkins et al. profile →
  11. Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study
    2005 550 citations Evanthia Galanis, Jan C. Buckner et al. Journal of Clinical Oncology profile →
  12. Efficacy of Bilateral Prophylactic Mastectomy in BRCA1 and BRCA2 Gene Mutation Carriers
    2001 546 citations Robert B. Jenkins et al. profile →
  13. A t(1;19)(q10;p10) Mediates the Combined Deletions of 1p and 19q and Predicts a Better Prognosis of Patients with Oligodendroglioma
    2006 533 citations Robert B. Jenkins, Hilary Blair et al. Cancer Research profile →
  14. Phase III Trial of Chemotherapy Plus Radiotherapy Compared With Radiotherapy Alone for Pure and Mixed Anaplastic Oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402
    2006 508 citations Gregory Cairncross, Brian Berkey et al. Journal of Clinical Oncology profile →
  15. The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression
    2013 489 citations Robert B. Jenkins, Jann N. Sarkaria et al. profile →
  16. Discovery and Validation of a Prostate Cancer Genomic Classifier that Predicts Early Metastasis Following Radical Prostatectomy
    2013 427 citations Nicholas Erho, Thomas M. Kollmeyer et al. profile →
  17. cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas
    2020 310 citations Caterina Giannini, Robert B. Jenkins et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robert B. Jenkins United States 89 13.0k 11.5k 11.2k 10.0k 9.6k 400 34.9k
Elizabeth A. Eisenhauer Canada 61 12.0k 0.9× 7.3k 0.6× 15.2k 1.4× 12.7k 1.3× 12.6k 1.3× 213 41.9k
Roger E. McLendon United States 90 19.5k 1.5× 11.8k 1.0× 12.9k 1.2× 5.3k 0.5× 18.7k 1.9× 330 42.0k
Darell D. Bigner United States 103 22.1k 1.7× 10.4k 0.9× 15.6k 1.4× 6.5k 0.7× 18.5k 1.9× 623 48.1k
Henry S. Friedman United States 95 15.0k 1.2× 7.5k 0.7× 9.0k 0.8× 7.9k 0.8× 21.5k 2.2× 567 38.4k
Charles L. Sawyers United States 99 24.8k 1.9× 9.3k 0.8× 12.3k 1.1× 15.9k 1.6× 11.6k 1.2× 266 53.4k
Webster K. Cavenee United States 99 31.7k 2.4× 13.7k 1.2× 12.7k 1.1× 8.8k 0.9× 22.4k 2.3× 315 62.0k
Patrick Y. Wen United States 102 12.3k 0.9× 8.0k 0.7× 9.9k 0.9× 11.6k 1.2× 23.9k 2.5× 781 43.2k
Denis Lacombe Belgium 34 9.2k 0.7× 7.7k 0.7× 15.2k 1.4× 14.2k 1.4× 12.8k 1.3× 113 41.0k
Hiroko Ohgaki France 69 16.6k 1.3× 11.3k 1.0× 6.0k 0.5× 6.9k 0.7× 23.9k 2.5× 168 42.6k
Kenneth Aldape United States 90 13.1k 1.0× 8.1k 0.7× 6.6k 0.6× 4.8k 0.5× 11.2k 1.2× 369 27.8k

Countries citing papers authored by Robert B. Jenkins

Since Specialization
Citations

This map shows the geographic impact of Robert B. Jenkins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert B. Jenkins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert B. Jenkins more than expected).

Fields of papers citing papers by Robert B. Jenkins

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert B. Jenkins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert B. Jenkins. The network helps show where Robert B. Jenkins may publish in the future.

Co-authorship network of co-authors of Robert B. Jenkins

This figure shows the co-authorship network connecting the top 25 collaborators of Robert B. Jenkins. A scholar is included among the top collaborators of Robert B. Jenkins based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert B. Jenkins. Robert B. Jenkins is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jenkins, Robert B., et al.. (2024). Prognostic factors of grade 4 IDH-mutant astrocytoma.. Journal of Clinical Oncology. 42(16_suppl). e14019–e14019.
2.
Wendt, George A., Lucie McCoy, Helen M. Hansen, et al.. (2024). Functional germline variants in DNA damage repair pathways are associated with altered survival in adults with glioma treated with temozolomide. Neuro-Oncology. 27(5). 1385–1398.
3.
Vaubel, Rachael A., Rahul Kumar, Taylor M. Weiskittel, et al.. (2023). Genomic markers of recurrence risk in atypical meningioma following gross total resection. Neuro-Oncology Advances. 5(1). vdad004–vdad004. 15 indexed citations
4.
Eckel‐Passow, Jeanette E., Daniel H. Lachance, Paul A. Decker, et al.. (2022). Inherited genetics of adult diffuse glioma and polygenic risk scores—a review. Neuro-Oncology Practice. 9(4). 259–270. 3 indexed citations
5.
Kollmeyer, Thomas M., Corinne Praska, Caterina Giannini, et al.. (2020). Frequency of false-positive FISH 1p/19q codeletion in adult diffuse astrocytic gliomas. Neuro-Oncology Advances. 2(1). vdaa109–vdaa109. 28 indexed citations
6.
Jaeckle, Kurt A., Erin Twohy, Jesse G. Dixon, et al.. (2019). Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG). Journal of Neuro-Oncology. 143(3). 573–581. 8 indexed citations
7.
Rounbehler, Robert J., Anders Berglund, Travis Gerke, et al.. (2018). Tristetraprolin Is a Prognostic Biomarker for Poor Outcomes among Patients with Low-Grade Prostate Cancer. Cancer Epidemiology Biomarkers & Prevention. 27(11). 1376–1383. 7 indexed citations
8.
9.
Walsh, Kyle M., Adam J. de Smith, Helen M. Hansen, et al.. (2015). A Heritable Missense Polymorphism in CDKN2A Confers Strong Risk of Childhood Acute Lymphoblastic Leukemia and Is Preferentially Selected during Clonal Evolution. Cancer Research. 75(22). 4884–4894. 31 indexed citations
10.
Cairncross, J. Gregory, Meihua Wang, Robert B. Jenkins, et al.. (2014). Benefit From Procarbazine, Lomustine, and Vincristine in Oligodendroglial Tumors Is Associated With Mutation of IDH. Journal of Clinical Oncology. 32(8). 783–790. 285 indexed citations
11.
Cairncross, Gregory, Meihua Wang, Edward Shaw, et al.. (2012). Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402. Journal of Clinical Oncology. 31(3). 337–343. 757 indexed citations breakdown →
12.
Bender, Aaron M., Lara S. Collier, Fausto J. Rodríguez, et al.. (2010). Sleeping Beauty –Mediated Somatic Mutagenesis Implicates CSF1 in the Formation of High-Grade Astrocytomas. Cancer Research. 70(9). 3557–3565. 52 indexed citations
13.
Collier, Lara S., David J. Adams, Christopher S. Hackett, et al.. (2009). Whole-Body Sleeping Beauty Mutagenesis Can Cause Penetrant Leukemia/Lymphoma and Rare High-Grade Glioma without Associated Embryonic Lethality. Cancer Research. 69(21). 8429–8437. 59 indexed citations
14.
Steensma, David P., Julie C. Porcher, Jonathan J. Keats, et al.. (2009). Rearrangements and Amplification of IER3 ( IEX-1 ) Represent a Novel and Recurrent Molecular Abnormality in Myelodysplastic Syndromes. Cancer Research. 69(19). 7518–7523. 34 indexed citations
15.
McCollum, Andrea K., Cynthia J. TenEyck, Bridget Stensgard, et al.. (2008). P-Glycoprotein–Mediated Resistance to Hsp90-Directed Therapy Is Eclipsed by the Heat Shock Response. Cancer Research. 68(18). 7419–7427. 57 indexed citations
16.
Bethel, Carlise R., Dennis Faith, Bin Guan, et al.. (2006). Decreased NKX3.1 Protein Expression in Focal Prostatic Atrophy, Prostatic Intraepithelial Neoplasia, and Adenocarcinoma: Association with Gleason Score and Chromosome 8p Deletion. Cancer Research. 66(22). 10683–10690. 117 indexed citations
17.
Jenkins, Robert B., Hilary Blair, Karla V. Ballman, et al.. (2006). A t(1;19)(q10;p10) Mediates the Combined Deletions of 1p and 19q and Predicts a Better Prognosis of Patients with Oligodendroglioma. Cancer Research. 66(20). 9852–9861. 533 indexed citations breakdown →
18.
Cairncross, Gregory, Brian Berkey, Edward Shaw, et al.. (2006). Phase III Trial of Chemotherapy Plus Radiotherapy Compared With Radiotherapy Alone for Pure and Mixed Anaplastic Oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. Journal of Clinical Oncology. 24(18). 2707–2714. 508 indexed citations breakdown →
19.
Lindor, Noralane M., Christopher Dechet, Mark H. Greene, et al.. (2001). Papillary Renal Cell Carcinoma: Analysis of Germline Mutations in the MET Proto-Oncogene in a Clinic-Based Population. Genetic Testing. 5(2). 101–106. 29 indexed citations
20.
Persons, Diane L., Lynn C. Hartmann, John F. Herath, et al.. (1993). Interphase molecular cytogenetic analysis of epithelial ovarian carcinomas.. PubMed. 142(3). 733–41. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Elizabeth A. Eisenhauer Breakdown of academic impact, for papers by Roger E. McLendon Breakdown of academic impact, for papers by Darell D. Bigner Breakdown of academic impact, for papers by Henry S. Friedman Breakdown of academic impact, for papers by Charles L. Sawyers Breakdown of academic impact, for papers by Webster K. Cavenee Breakdown of academic impact, for papers by Patrick Y. Wen Breakdown of academic impact, for papers by Denis Lacombe Breakdown of academic impact, for papers by Hiroko Ohgaki Breakdown of academic impact, for papers by Kenneth Aldape
Rankless by CCL
2026